Dyne Therapeutics (DYN) Cash from Financing Activities (2020 - 2026)
Dyne Therapeutics (DYN) posted quarterly Cash from Financing Activities of $58.1 million for Q2 2026, down 42.34% year-over-year from $100.8 million in Q2 2025, and up 722.62% quarter-over-quarter from $7.1 million in Q1 2026.
Dyne Therapeutics (DYN) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Cash from Financing Activities for 7 consecutive years, with $58.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Financing Activities fell 42.34% year-over-year to $58.1 million; the TTM figure through Jun 2026 stood at $713.5 million (up 170.6% YoY), while the FY2025 annual figure was $890.3 million, up 9.93% from the prior year.
- Cash from Financing Activities grew to $58.1 million in Q2 2026 per DYN's latest filing, from $7.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $431.0 million in Q4 2025 and bottomed at $18000.0 in Q1 2022.
- Historically, Cash from Financing Activities has averaged $103.2 million across 5 years, with a median of $26.9 million in 2023.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 99.99% — and 2023, when it surged 159983.33%.
- Dyne Therapeutics' Cash from Financing Activities stood at $37.2 million in 2022, then tumbled by 99.6% to $147000.0 in 2023, then surged by 2373.47% to $3.6 million in 2024, then surged by 11752.72% to $431.0 million in 2025, then slumped by 86.52% to $58.1 million in 2026.
- Business Quant data shows DYN's Cash from Financing Activities at $58.1 million in Q2 2026, $7.1 million in Q1 2026, and $431.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | 58.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.11 Mn |
| Jun 30, 2026 | 58.11 Mn |
| Mar 31, 2026 | 7.06 Mn |
| Mar 31, 2026 | 7.06 Mn |
| Dec 31, 2025 | 430.97 Mn |
| Dec 31, 2025 | 430.97 Mn |
| Sep 30, 2025 | 217.33 Mn |
| Sep 30, 2025 | 217.33 Mn |
| Jun 30, 2025 | 100.77 Mn |
| Jun 30, 2025 | 100.77 Mn |
| Mar 31, 2025 | 141.24 Mn |
| Mar 31, 2025 | 141.24 Mn |
| Dec 31, 2024 | 3.64 Mn |
| Dec 31, 2024 | 3.64 Mn |
| Sep 30, 2024 | 18.01 Mn |
| Sep 30, 2024 | 18.01 Mn |
| Jun 30, 2024 | 379.86 Mn |
| Jun 30, 2024 | 379.86 Mn |
| Mar 31, 2024 | 408.39 Mn |
| Mar 31, 2024 | 408.39 Mn |